Last reviewed · How we verify
NCT06357663
Subtle Energy Transmission and Tao Calligraphy Mindfulness in Telomere Length in Peripheral Blood Leukocytes
NA trial testing Mindfulness practice with Calligraphy in Telomere Length in 12 participants. Terminated before completion.
31 July 2024
Quick facts
| Lead sponsor | Sha Research Foundation |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 12 |
| Start date | 15 June 2023 |
| Primary completion | 31 July 2024 |
| Estimated completion | 25 March 2025 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Mindfulness practice with Calligraphy
Conditions studied
- Telomere Length — all drugs for Telomere Length →
- Quality of Life — all drugs for Quality of Life →
Sponsor
Sha Research Foundation
Who can join
60 and older, any sex, with Telomere Length or Quality of Life. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Effect of Subtle Energy Transmission and Tao Calligraphy Mindfulness Practice on Telomere Length in Peripheral Blood Leukocytes A Follow-up Pilot Study The goal of this Pilot clinical trial is to learn if a Subtle Energy Transmission and Tao Calligraphy Mindfulness Practice works to increase Telomere Length in Peripheral Blood Leukocytes in adults. The main questions it aims to answer are: * Does A Subtle energy transmission and Tao Calligraphy Mindfulness increase Telomere Length in Peripheral Blood Leukocytes in adults? * Will this increase of Telomere Length in Peripheral Blood Leukocytes in adults be statistically significant? Researchers will compare the length of Telomere in peripheral blood Leukocytes at beginning of the mindfulness practices to the length of Telomere in peripheral blood Leukocytes at 3 months and at 9 months of regular daily practices. Participants will: * Receive a transmission of Subtle energy at beginning of practices * Visit the Laboratory for a blood sample taken at beginning, at 3 months and at 9 months of practices. * Fill the Study Questionnaires at beginning, at 3 months and at 9 months of practices. * Practice the Mindfulness with Tao Calligraphy daily 1 hour in the morning and 1 hour in the evening.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06357663
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Telomere Length
Currently open trials in the same condition.
- NCT06732843 — Does Recombinant FSH (rFSH, i.g. Gonal F®) as Compared to Human Menopausal Gonadotrophin (hMG) Affect Telomere Length of · recruiting
Other Sha Research Foundation trials
Trials by the same sponsor.
- NCT07261111 — Effect of Subtle Energy Transmission and Tao Calligraphy Mindfulness Practice on Mitochondrial DNA in Peripheral Blood L · NA · not yet recruiting
- NCT06803641 — The Effects of Mindfulness Practice With Tao Art (Love Peace Harmony Calligraphy and Song) on Well-being · NA · recruiting
- NCT06934330 — Effect of Tao Calligraphy Meditation and Energized Water on Depression · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06357663 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sha Research Foundation
- Last refreshed: 15 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06357663.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing